Bremelanotide (PT-141) CAS 189691-06-3 Purity ≥99.0% (HPLC)

Short Description:

Chemical Name: Bremelanotide (PT-141)

Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH

CAS: 189691-06-3

Purity: ≥99.0% (HPLC)

Appearance: White Powder 

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

189691-06-3 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Bremelanotide (PT-141) (CAS: 189691-06-3) with high quality. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Bremelanotide (PT-141), Please contact: alvin@ruifuchem.com

189691-06-3 - Chemical Properties:

Chemical Name Bremelanotide (PT-141)  
Sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Synonyms PT141; N-Acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysine (2-7)-lactam
Stock Status In Stock, Commercial Production  
CAS Number 189691-06-3 
Molecular Formula C50H68N14O10
Molecular Weight 1025.16 g/mol
Density 1.43 g/ml 
COA & MSDS Available
HPLC Result Enclosed
Mass Spec. Enclosed
Place of Origin  Shanghai, China
Brand Ruifu Chemical

189691-06-3 - Specifications:

Items Specifications 
Appearance White Powder 
Amino Acid Composition  ±10% of Theoretical
Purity (HPLC) ≥99.0% (HPLC) 
Single Impurity (HPLC)  ≤1.00%
Water Content (Karl Fischer) ≤6.00%
Acetate Content (HPIC) ≤15.00%
Mass Spectrum   In Accordance with the Standard
IR Spectrum In Accordance with the Standard
Conclusion The product has been tested and complies with the given specifications
Note All peptides are shipped as lyophilized powder. It’s for research use only.

189691-06-3 - Disclaimer:

The products will be supplied to some countries in which it could be in conflict with existing patents. However the final responsibility lies exclusively with the buyer.
The products are for research or lab use only, not intended for human use. 

189691-06-3 - HPLC Result:

HPLC Result as Follows:

Project Name: PT-141                                     Processing Method: G.E

Injection Volume: 20.00ul                               Run Mode: Analysis

Run Time: 30 Minutes                                      Lambda: 220nm

Peak Results

                                                                                                 

Peak No         Ret time            Peak Height              Peak Area           Result

1              14.910              2842.589                24279.842           0.4177

   2              15.140              534150.625              5768839.500        99.2340

  3              17.172              2670.344                20248.998           0.3483       

                                     539663.558              5813368.340        100.0000

Method Information

Merck (250×4.6mm I.D.) C18                             Buffer A: 0.10% TFA+CH3CN

Flow Rate: 1.0ml/min                                    Buffer B: 0.10% TFA+H2O

Gradient: 30%-60%A in 0-30 minutes

Package/Storage/Shipping:

Package: Bottle, vial, vacuum packing. Accurate to the milligram as required.
Storage: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture. And avoid frequent thawing and freezing.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery. 

Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock    

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com 

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality AssuranceStrict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

SamplesMost products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory AuditFactory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

TransportationBy Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom SynthesisCan provide custom synthesis services to best fit your research needs.

Payment TermsProforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc. 

189691-06-3 - Application:

Bremelanotide (PT-141) (CAS: 189691-06-3) was approved by the FDA in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. Bremelanotide activates melanocortin receptors,but the mechanism by which it improves sexual desire is unknown. To use bremelanotide, women inject it under the skin ofthe abdomen or thigh at least 45 minutes before anticipated sexual activity.The optimal time to inject bremelanotide may vary based on the duration of benefit and side effects experienced. More than one dose of bremelanotide should not be used within 24 hours or more than eight doses per month. Common side effects include nausea, vomiting, flushing, injection site reactions, and headache. Bremelanotide should not be used in women with high blood pressure that is uncontrolled or in those with known cardiovascular disease, and it is not recommended for women at high risk for cardiovascular disease. The safety and efficacy of bremelanotide has not been studied in breast cancer survivors, and there are no recommendations regarding its use in this population.

  • Write your message here and send it to us